PROCEPT BioRobotics Corporation Investors: September 22, 2026, Deadline in Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy PRCT common stock between February 28, 2024 and February 25, 2026? Kessler Topaz Meltzer & Check, LLP Affected PRCT Investor Summary Who: PROCEPT BioRobotics Corporation ( NASDAQ: PRCT ) What: Securities fraud class action lawsuit filed Class Period: February 28, 2024 through February 25, 2026 Deadline to Seek Lead Plaintiff Status: September 22, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s product demand Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation (PROCEPT) (NASDAQ: PRCT) on behalf of those who purchased or acquired PROCEPT common stock between February 28, 2024 and February 25, 2026, inclusive. The lawsuit is filed in the United States District Court for the Norther District of California and is captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.). Investors have until September 22, 2026, to file for lead plaintiff status. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired PROCEPT common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/prct-procept-biorobotics-corporation-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=prct&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. PROCEPT BIOROBOTICS CORPORATION CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY: PROCEPT is a commercial stage medical technology company focused primarily on the treatment of benign prostatic hyperplasia (“BPH”), also known as an enlarged prostate. One of the devices that PROCEPT manufactured and sold for the treatment of BPH was an Aquablation therapy system that utilized a single-use handpiece that was disposed of after the procedure. The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) PROCEPT utilized a discount program to incentivize customers to place bulk orders in excess of demand; (2) the undisclosed discount program artificially inflated the company’s reported U.S. handpiece unit sales; (3) the consistent surplus of U.S. handpiece unit sales results in overstocking and exposed PROCEPT to material undisclosed risks of operational and financial harm; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Why did PROCEPT’S Stock Drop? On February 25, 2026, PROCEPT announced its financial earnings for the year 2025 and the first quarter of 2026. Specifically, PROCEPT revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, despite consistent reassurances to the contrary. On this news, the price of PROCEPT’s common stock fell more than 18%. WHAT PROCEPT BIOROBOTICS CORPORATION INVESTORS CAN DO NOW: File to be lead plaintiff by September 22, 2026. Contact KTMC for a free case evaluation.